Novel C-4'' modified azithromycin analogs with remarkably enhanced activity against erythromycin-resistant Streptococcus pneumoniae: the synthesis and antimicrobial evaluation

Eur J Med Chem. 2011 Oct;46(10):5196-205. doi: 10.1016/j.ejmech.2011.08.001. Epub 2011 Aug 7.

Abstract

Three novel structural series of C-4'' modified azithromycin analogs with two amide groups, which were connected by different alkyl linkage, were designed, prepared and evaluated for their in vitro antibacterial activity against seven phenotypes of respiratory pathogens. Among them, 7d, 8j and 9j, as representatives of corresponding series, exhibited remarkably improved activity against erythromycin-resistant Streptococcus pneumoniae expressing the erm gene, the mef gene, and the erm and mef genes. In addition, 7a-c, 7f-h, 7j, 8d, 8g, 8i, 9a-b and 9i displayed favorable efficacy against erythromycin-resistant S. pneumoniae A22072 expressing the mef gene.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / chemical synthesis
  • Anti-Bacterial Agents / chemistry*
  • Anti-Bacterial Agents / pharmacology*
  • Azithromycin / analogs & derivatives*
  • Azithromycin / chemical synthesis
  • Azithromycin / pharmacology*
  • Bacterial Proteins / genetics
  • Drug Resistance, Bacterial*
  • Erythromycin / pharmacology*
  • Gene Expression
  • Humans
  • Membrane Proteins / genetics
  • Microbial Sensitivity Tests
  • Pneumococcal Infections / drug therapy
  • Streptococcus pneumoniae / drug effects*
  • Streptococcus pneumoniae / genetics

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • MefA protein, Streptococcus
  • Membrane Proteins
  • Erythromycin
  • Azithromycin